Q: What is Breyanzi used for?

Breyanzi is used to treat large B-cell lymphoma .

Q: What are the active ingredients in Breyanzi?

The active ingredient in Breyanzi is lisocabtagene maraleucel .

Q: What are the side effects of Breyanzi?

Common side effects of Breyanzi may include: fever fatigue nausea and others Always consult with a healthcare professional about potential side effects.

Q: What drug class is Breyanzi?

Breyanzi belongs to the CAR T-cell therapy drug class.

Q: What is the dosage of Breyanzi and how do I take it?

Administration Process Breyanzi is a personalized therapy created from your own white blood cells. The process begins with a procedure to collect these cells from your blood. The cells are then sent to a laboratory where they are modified to recognize and attack specific cancer cells before being sent back to the healthcare facility for your treatment. Before the Infusion A few days before receiving Breyanzi, you will typically receive a short course of chemotherapy to prepare your immune system for the modified cells. Shortly before the infusion begins, your healthcare provider will give you other medications, such as acetaminophen and an antihistamine, to help prevent reactions during the procedure. How It Is Given The medication is administered as an injection into a vein (intravenous infusion) by a healthcare professional. This is a single-dose treatment. Because of the specialized nature of this therapy, it is only available at certified healthcare facilities. After the infusion, you will be required to stay near the treatment center for several weeks so your medical team can monitor your progress and check for any side effects.

Q: Is Breyanzi safe during pregnancy and breastfeeding?

Pregnancy It is not known if Breyanzi will harm an unborn baby. There are no available data on the use of this medication in pregnant individuals, and animal reproduction studies have not been performed to evaluate its effects on fetal development. Patients should inform their healthcare provider if they are pregnant or planning to become pregnant before starting treatment to discuss potential risks and benefits. Breastfeeding It is unknown whether Breyanzi passes into breast milk or if it could affect a nursing child. Due to the potential for transmission of the viral vector used during the manufacturing process of this cell therapy, breastfeeding is generally not recommended. Patients should discuss infant feeding options with their healthcare team before beginning treatment.

Q: What is the FDA approval status of Breyanzi?

FDA Approval and Indications Breyanzi (lisocabtagene maraleucel) was first approved by the U.S. Food and Drug Administration (FDA) in 2021. It is a chimeric antigen receptor (CAR) T-cell therapy indicated for the treatment of adults with several types of B-cell malignancies that have not responded to previous treatments or have returned after treatment. Approved indications include: Large B-cell lymphoma (LBCL) Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) Follicular lymphoma (FL) Mantle cell lymphoma (MCL) Marginal zone lymphoma (MZL) Boxed Warning The FDA has issued a Boxed Warning for Breyanzi due to the risk of serious and potentially life-threatening side effects, including: Cytokine Release Syndrome (CRS): A systemic inflammatory response that can cause high fever, chills, and multi-organ failure. Neurologic Toxicities: Serious brain and nervous system reactions, such as confusion, altered consciousness, or seizures. Because of these risks, Breyanzi is only available through a restricted program called the Breyanzi Risk Evaluation and Mitigation Strategy (REMS). Healthcare facilities must be specially certified to administer the treatment and manage these potential complications. Safety Communications The FDA has issued safety communications regarding the risk of secondary T-cell malignancies following treatment with CAR T-cell therapies, including Breyanzi. While the FDA has determined that the overall benefits of these therapies continue to outweigh their potential risks for their approved uses, the agency requires manufacturers to include information about this risk in the prescribing information and continues to monitor reports of new cancers.

Question 1

What is Breyanzi?

Accepted Answer

Breyanzi is a chimeric antigen receptor (CAR) T-cell therapy, which is a type of immunotherapy that uses the body's own immune system to fight cancer. It is made from a patient's own white blood cells that have been genetically modified to better identify and attack cancer cells.

These modified cells are engineered to recognize a specific protein found on the surface of certain cancer cells. This allows the immune system to more effectively target and eliminate the cancer within the body.

Question 2

What is Breyanzi used for?

Accepted Answer

Breyanzi is used to treat large B-cell lymphoma.

Question 3

How does Breyanzi work?

Accepted Answer

Breyanzi is a type of immunotherapy known as autologous cellular therapy. It works by reprogramming a patient's own white blood cells, specifically T cells, to identify and attack cancer. T cells are a vital part of the immune system that normally help the body fight infections.

The process of how this treatment works involves several key stages:

Cell Collection: T cells are first collected from the patient's blood through a process similar to donating blood.
Genetic Engineering: In a specialized laboratory, these T cells are genetically modified to produce a specific protein on their surface called a chimeric antigen receptor (CAR).
Targeting: This new receptor is designed to recognize and bind to a protein called CD19. CD19 is found on the surface of many types of B-cell lymphoma and leukemia cells.
Expansion and Infusion: After the modified cells are grown in large numbers, they are infused back into the patient's bloodstream.

Once inside the body, these modified T cells circulate and search for cells that have the CD19 protein. When the CAR T cells attach to these cancer cells, they activate the immune system to destroy the targeted cells. Because the treatment uses the patient's own cells, it is a highly personalized form of medicine.

Question 4

What are the active ingredients in Breyanzi?

Accepted Answer

The active ingredient in Breyanzi is lisocabtagene maraleucel.

Question 5

What are the side effects of Breyanzi?

Accepted Answer

Common side effects of Breyanzi may include:

fever
fatigue
nausea
and others

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Breyanzi?

Accepted Answer

Breyanzi belongs to the CAR T-cell therapy drug class.

Question 7

What is the dosage of Breyanzi and how do I take it?

Accepted Answer

Administration Process

Breyanzi is a personalized therapy created from your own white blood cells. The process begins with a procedure to collect these cells from your blood. The cells are then sent to a laboratory where they are modified to recognize and attack specific cancer cells before being sent back to the healthcare facility for your treatment.

Before the Infusion

A few days before receiving Breyanzi, you will typically receive a short course of chemotherapy to prepare your immune system for the modified cells. Shortly before the infusion begins, your healthcare provider will give you other medications, such as acetaminophen and an antihistamine, to help prevent reactions during the procedure.

How It Is Given

The medication is administered as an injection into a vein (intravenous infusion) by a healthcare professional. This is a single-dose treatment. Because of the specialized nature of this therapy, it is only available at certified healthcare facilities. After the infusion, you will be required to stay near the treatment center for several weeks so your medical team can monitor your progress and check for any side effects.

Question 8

Is Breyanzi safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

It is not known if Breyanzi will harm an unborn baby. There are no available data on the use of this medication in pregnant individuals, and animal reproduction studies have not been performed to evaluate its effects on fetal development. Patients should inform their healthcare provider if they are pregnant or planning to become pregnant before starting treatment to discuss potential risks and benefits.

Breastfeeding

It is unknown whether Breyanzi passes into breast milk or if it could affect a nursing child. Due to the potential for transmission of the viral vector used during the manufacturing process of this cell therapy, breastfeeding is generally not recommended. Patients should discuss infant feeding options with their healthcare team before beginning treatment.

Question 9

What forms and strengths does Breyanzi come in?

Accepted Answer

Breyanzi is available as a suspension for intravenous infusion. It is an autologous immunotherapy, which means it is a personalized treatment manufactured specifically for each patient using their own white blood cells (T cells).

The medication is supplied in vials containing two separate components that are administered together as a single treatment:

CD8 component
CD4 component

The strength of the dose is determined by the number of chimeric antigen receptor (CAR)-positive viable T cells. Because each dose is custom-made for the individual patient, the exact volume and cell concentration may vary within a standardized range defined by the manufacturer.

Question 10

What is the FDA approval status of Breyanzi?

Accepted Answer

FDA Approval and Indications

Breyanzi (lisocabtagene maraleucel) was first approved by the U.S. Food and Drug Administration (FDA) in 2021. It is a chimeric antigen receptor (CAR) T-cell therapy indicated for the treatment of adults with several types of B-cell malignancies that have not responded to previous treatments or have returned after treatment. Approved indications include:

Large B-cell lymphoma (LBCL)
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Follicular lymphoma (FL)
Mantle cell lymphoma (MCL)
Marginal zone lymphoma (MZL)

Boxed Warning

The FDA has issued a Boxed Warning for Breyanzi due to the risk of serious and potentially life-threatening side effects, including:

Cytokine Release Syndrome (CRS): A systemic inflammatory response that can cause high fever, chills, and multi-organ failure.
Neurologic Toxicities: Serious brain and nervous system reactions, such as confusion, altered consciousness, or seizures.

Because of these risks, Breyanzi is only available through a restricted program called the Breyanzi Risk Evaluation and Mitigation Strategy (REMS). Healthcare facilities must be specially certified to administer the treatment and manage these potential complications.

Safety Communications

The FDA has issued safety communications regarding the risk of secondary T-cell malignancies following treatment with CAR T-cell therapies, including Breyanzi. While the FDA has determined that the overall benefits of these therapies continue to outweigh their potential risks for their approved uses, the agency requires manufacturers to include information about this risk in the prescribing information and continues to monitor reports of new cancers.

Question 11

What should I know about Breyanzi and cost?

Accepted Answer

Factors Influencing Cost

Breyanzi is a personalized CAR-T cell therapy, which involves a complex manufacturing process using a patient's own white blood cells. Because it is a specialized, one-time treatment, the cost is typically high. Several variables determine the final amount a patient may pay:

Insurance Coverage: Most private insurance plans, Medicare, and Medicaid may cover CAR-T cell therapy, but out-of-pocket costs such as deductibles, copayments, or coinsurance will vary by plan.
Treatment Center: Breyanzi is only administered at certified healthcare facilities. These centers may have different billing structures for the infusion procedure and the required hospital stay.
Associated Medical Services: The total cost often includes more than the drug itself, such as the collection of cells (leukapheresis), laboratory processing, and intensive monitoring for side effects after the treatment.

Financial Assistance

The manufacturer of Breyanzi often provides patient support services to help navigate the insurance process. These programs may offer financial assistance or cost-sharing support for eligible patients. It is recommended that patients speak with a financial counselor or social worker at their authorized treatment center to get a detailed estimate of costs and explore available support options.

Breyanzi

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Breyanzi

Hospitals.net Disclosure